



# 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

Boston, MA • March 28-29, 2025

## Friday, March 28, 2025

7:00 - 8:00	<b>BREAKFAST</b>	
8:00 - 8:10	<b>INTRODUCTION AND WELCOME</b>	
8:10 - 8:45	<b>PLENARY TALK</b>	Crystal Mackall
8:45 - 10:00	<b>SESSION 1: CLINICAL UPDATES ON CAR T CELLS</b> <i>Chairs: Pieter Sonneveld and Yi Lin</i>	
8:45 - 9:00	Ide-cel and Cilta-cel: latest data and ongoing trials	TBC
9:00 - 9:10	Real world data for BCMA CAR T cells	Surbhi Sidana
9:10 - 9:20	Novel autologous BCMA CAR T cells: latest data and ongoing trials	Matthew Frigault
9:20 - 9:30	Update on GPRC5D CAR T cells	Maung Myo Htut
9:30 - 10:00	Discussion	Session faculty + Francesca Gay
10:00 - 10:30	<b>BREAK</b>	
10:30 - 11:50	<b>SESSION 2: CLINICAL UPDATES ON BISPECIFIC ABS/TCE'S</b> <i>Chair: Jesus San Miguel</i>	
10:30 - 10:40	Teclistamab monotherapy and combinations: Latest data and ongoing trials	Maria-Victoria Mateos
10:40 - 10:50	Elranatamab monotherapy and combinations: Latest data and ongoing trials	Mohamad Mohty
10:50 - 11:00	Talquetamab monotherapy and combinations: Latest data and ongoing trials	Ajai Chari
11:00 - 11:10	Update on linvoseltamab, ABBV-383 and cevostamab	Joshua Richter
11:10 - 11:20	Real world data for bispecific antibodies	Susan Bal
11:20 - 11:50	Discussion	Session faculty + Marc Raab

11:50 - 1:00

**LUNCH**

---

1:00 - 2:30

**SESSION 3: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPY**

*Chairs: Saad Usmani and Hermann Einsele*

1:00 - 1:10	What's the best time to give CAR T Cells - frontline, 2nd line, or beyond?	Paula Rodriguez-Otero
1:10 - 1:20	How to manage relapse after CAR T cells or Bispecifics	Krina Patel
1:20 - 1:30	Using CAR T cells and bispecific Abs for AL amyloidosis	Eyal Lebel
1:30 - 1:40	CAR T cell and Bi-specific in SMM	Omar Nadeem
1:40 - 1:50	How to utilize belantamab mafodotin in a T cell-engaging world	Suzanne Trudel
1:50 - 2:00	Sustaining an academic CAR T Cell program	Alvaro Urbano-Ispizua
2:00 - 2:30	Discussion	Session faculty + Vania Hungria

---

2:30 - 3:00

**BREAK**

---

3:00 - 4:20

**SESSION 4: NOVEL APPROACHES IN THE CLINIC**

*Chairs: Philippe Moreau and Noopur Raje*

3:00 - 3:10	Allogeneic/off-the-shelf CAR T cells - still worth pursuing?	Bhagirathbhai Dholaria
3:10 - 3:20	Dual antigen targeting with CAR T cells and trispecific antibodies	Jesus Berdeja
3:20 - 3:30	CAR-NK cells and NK-targeting bispecifics	Joaquin Martinez Lopez
3:30 - 3:40	Novel targets for CAR-T in MM	Michael Hudecek
3:40 - 3:50	Combining CAR T cells and bispecific Abs	Adam Cohen
3:50 - 4:20	Discussion	Session faculty + Eric Smith

---

4:20 - 5:30

**SESSION 5: MANAGING TOXICITIES OF T CELL ENGAGING THERAPIES**

*Chair: Simon Harrison*

4:20 - 4:30	Should we be using prophylactic tocilizumab?	Jonathan Kaufman
4:30 - 4:40	Mitigating talquetamab-related oral and skin toxicities	TBC
4:40 - 4:50	Immune effector cell-associated enterocolitis	Noffar Bar
4:50 - 5:00	Stem cell rescue for persistent cytopenias post-CAR T cells	TBC
5:00 - 5:30	Discussion	Session faculty + Binod Dhakal

---

5:30 - 5:45

**CONCLUSION**

# Saturday, March 29, 2025

7:00 - 8:00

## BREAKFAST

---

8:00 - 8:05

## WELCOME

---

8:05 - 9:25

## SESSION 6: CORRELATES OF RESPONSE AND RESISTANCE

*Chairs: Niccolo Bolli and Kwee Yong*

8:05 - 8:15

T cell factors impacting response to CAR T cell therapy

TBC

8:15 - 8:25

Microenvironment factors impacting response to CAR T cell therapy

Samir Parekh

8:25 - 8:35

Novel resistance mechanisms to bispecific Ab therapy

Nizar Bahlis

8:35 - 8:45

Tumor genomics and response to immune therapy

TBC

8:45 - 8:55

Circulating tumor DNA to predict response/resistance

Johannes Waldschmidt

8:55 - 9:15

Discussion

Session faculty +  
Mehmet Samur

---

9:15 - 10:30

## SESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPIES

*Chairs: Amrita Krishnan and Madhav Dhodapkar*

9:15 - 9:25

CellMOD's to enhance safety and efficacy of CAR T cells and bispecific Abs

Marta Larrayoz

9:25 - 9:35

CAR-enhancers for myeloma

Mohammad Rashidian

9:35 - 9:45

In vivo T cell engineering

Adi Barzel

9:45 - 9:55

Overcoming T cell exhaustion and tumor resistance

Marco Ruella

9:55 - 10:05

Combine T cell engaging therapy with vaccination

David Avigan

10:05 - 10:30

Discussion

Session faculty +  
Niels van de Donk

---

10:30 - 11:00

## BREAK

---

11:00 - 12:00

## SESSION 8: KEY QUESTIONS IN IMMUNE THERAPY

*Chairs: Sonja Zweegman and Hearn Cho*

11:00 - 11:10

Can we cure myeloma with "Total Immune Therapy"?

Sagar Lonial

11:10 - 11:20

Is MRD a viable endpoint for immune effector cell therapy trials?

Nikhil Munshi

11:20 - 11:30

Which target should we hit first: BCMA or GPRC5D (or Both)?

Sham Mailankody

11:30 - 11:40

Is immune profiling useful for predicting response to T cell directed therapies?

Bruno Paiva

11:40 - 12:15

Discussion

Session faculty +  
Cyrille Touzeau

---

12:15 - 1:15

## LUNCH

---

1:15 - 2:15

**WORKSHOP ON SECONDARY MALIGNANCIES  
AND NON-RELAPSE MORTALITY**

*Chair: Kenneth Anderson*

1:15 - 1:25

Non-relapse mortality after CAR T cells

David Cordas dos Santos

1:25 - 1:35

Non-relapse mortality after Bispecific Abs

Meera Mohan

1:35 - 1:45

Myeloid and lymphoid malignancies after  
immune effector cell therapy

Adam Sperling

1:45 - 2:15

Discussion

Session faculty + Ajay Nooka

2:15

**CONCLUSION AND WRAP-UP**

**Thank you to our sponsors**

TITANIUM



PLATINUM



GOLD



SILVER

